SMTL ID : 8vy4.1

Engineering a Tumor-Selective Prodrug T Cell Engager Bispecific Antibody for Safer Immunotherapy

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 1.70 Å

Oligo State

hetero-1-1-mer

Ligands

1 x PCA- ASP- GLY- ASN- GLU- GLU- MET: PCA-ASP-GLY-ASN-GLU-GLU-MET(Non-covalent)

PCA-ASP-GLY-ASN-GLU-GLU-MET.1: 18 residues within 4Å: Chain A: A.32, F.49, A.51, V.52, Y.57, R.96, I.97, G.98, I.99, G.100, I.101 Chain B: Y.30, Y.34, Y.93, T.95, T.96, Y.99, I.101 21 PLIP interactions: 10 interactions with chain A, 11 interactions with chain B Hydrophobic interactions: A:V.52, A:I.99, B:Y.30, B:Y.93, B:Y.93, B:T.96, B:I.101 Hydrogen bonds: A:V.52, A:R.96, A:I.99, A:G.100, A:I.101, B:Y.93, B:Y.93, B:Y.93, B:T.95, B:Y.99 Water bridges: A:Y.57, A:R.96, B:Y.30 Salt bridges: A:R.96

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

McCue, A.C. et al., Engineering a tumor-selective prodrug T-cell engager bispecific antibody for safer immunotherapy. Mabs (2024)

Release Date

2024-07-24

Peptides

Fab Heavy Chain: A
Fab Light Chain: B

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

B
B

Fab Heavy Chain

Fab Light Chain